Last update Aug. 6, 2018
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Pridinol Mesilate in other languages or writings:
Pridinol Mesilate belongs to this group or family:
Main tradenames from several countries containing Pridinol Mesilate in its composition:
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Centrally acting muscle relaxant with anticholinergic effects.
At last update no published on excretion in breast milk data were found. Even on humans pharmacokinetic data is barely found.
Its anticholinergic effect has a theoretical risk of inhibiting lactation especially during the early postpartum weeks.
Until more data about this drug regarding breastfeeding is available, safer known alternatives should be of choice, especially in the neonatal period and in case of prematurity.
If administered during breastfeeding, use small doses and monitor drowsiness and adequate feeding of the infants.
(Not to be confused with the trademark Pridinol, which in some countries corresponds to Terfenadine)